Introduction {#s1}
============

Approximately 5--10% of patients infected with hepatitis B virus (HBV) as adults are unable to clear the virus, ultimately developing chronic HBV infections[@pone.0019606-Chisari1]. The persistence of the virus is thought to be largely caused by a deficiency of the immune response to HBV[@pone.0019606-Chisari1]. The virus itself, environment factors, ethnic differences, and genetic susceptibility have also been reported to have some influence on the progression of this liver disease [@pone.0019606-Wang1]. Recently, cytokine genetic polymorphisms have been found to be related factors that affect the progression of HBV infection [@pone.0019606-Chisari1].

Tumor necrosis factor *\<alpha\>* (*TNF-\<alpha\>*) is produced by macrophages, monocytes, neutrophils, T-cells and NK-cells after stimulation. In turn, *TNF-\<alpha\>* can stimulate cytokine secretion, increase the expression of adhesion molecules as well as activate neutrophils. Hence, it fulfills the role as a principal mediator of cellular immune response and inflammation, and may play an importance role in non-cytolytic and cytolytic clearance of HBV [@pone.0019606-Tokushige1], [@pone.0019606-Bozkaya1], [@pone.0019606-KamaliSarvestani1].

The *TNF-\<alpha\>* gene is located in the class III region of the major histocompatibility complex (MHC) on chromosome 6. The amount of cytokine production seems to be affected by the polymorphisms in the regulatory region. Therefore, there might be relationships between these single nucleotide polymorphisms (SNPs) and cytokine-mediated inflammation, which may affect the outcome of the disease.

There have been a number of studies on the association between chronic HBV infection (CHB), HBV clearance (HC), and *TNF-\<alpha\>* promoter polymorphisms -1031T/C, -863 C/A, -857C/T, -308G/A, and-238G/A. However, the results have been inconsistent. For instance, some studies indicated that patients carrying *TNF-\<alpha\>* genotypes (AA for -863, CC for -857, AA for -308, and AA for -283) have a higher risk of susceptibility to persistence of HBV [@pone.0019606-Chen1], [@pone.0019606-Kim1], [@pone.0019606-Niro1], [@pone.0019606-Hohler1] while other studies did not[@pone.0019606-Cheong1], [@pone.0019606-Ribeiro1], [@pone.0019606-Somi1].

A single study may fail to completely demonstrate this complicated genetic relationship because of a small sample size, which has low statistical power. Larger studies could overcome these disadvantages. Therefore, we performed a meta-analysis in an attempt to resolve this issue.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

We searched the PubMed, EMBASE, ISI Web of Science, Google Scholar, Chinese National Knowledge Infrastructure Database and China Biological Medicine Database to collect all papers associated *TNF-\<alpha\>* polymorphism and HBV (last search update: 31^st^ July 2010). The following key words were used: "hepatitis B", "HBV", "Tumor necrosis factor *\<alpha\>*", "*TNF-\<alpha\>*", "polymorphism" and "SNP". We also combined these key words to maximize the sample size in our analysis. *TNF-\<alpha\>* promoter polymorphisms -1031T/C, -863 C/A, -857C/T, -308G/A and-238G/A were investigated. The electronic searching was supplemented by checking reference lists from identified articles and reviews for additional original reports The language of the reviewed articles was limited to Chinese and English. Data were extracted by two authors independently and a consensus was achieved for all data. We excluded studies that were not full-length publications, and those that included no more than 10 participants. When study recruitment overlapped by more than 30% in two or more articles by the same author(s), the one with the largest population of participants or the most recent one was selected. We used Chi-square test to evaluate whether the observed frequencies of genotypes conformed to Hardy-Weinberg Equilibrium (HWE). CHB was defined as a condition in which serum HBsAg was positive for at least 6 months. HBV clearance (HC) was defined as a condition in which HBsAg was negative, but both HBV core antibody (anti-HBc) and HBV surface antibody (anti-HBs) were positive. None of the patients included in our study had any other type of liver disease such as hepatitis C or alcoholic liver disease.

Data extraction {#s2b}
---------------

The following information was extracted by two authors independently, and a consensus was achieved: first author\'s name, year of publication, country, mean age of the study subjects, gender component, genotyping method, cases of CHB and HC with various genotypes, polymorphisms of *TNF-\<alpha\>* promoter.

Statistical analysis {#s2c}
--------------------

Odds ratios (ORs) with their confidence intervals (CIs) were calculated for each study. Heterogeneity was tested by chi-square-based Q test and I^2^ = 100%×(Q-df)/Q [@pone.0019606-Lau1], [@pone.0019606-Higgins1]. The fixed effects model (Mantel--Haenszel method) [@pone.0019606-Mantel1] was used for calculating the pooled OR when the *P* value \>0.05 for the Q test which indicated absence of heterogeneity among the studies. Otherwise, we used a random-effects model (DerSimonian-Laird method). Publication bias tests were performed by using the funnel plot, in which the standard error of log (OR) of each study was plotted against its log (OR). Funnel plot asymmetry was evaluated by Egger\'s linear regression test. A *P* value \<0.10 was considered to indicate statistically significant publication bias.

Results {#s3}
=======

Extraction process and characteristics of the studies {#s3a}
-----------------------------------------------------

One hundred and six studies were identified after searching the databases. Seventy-six studies that not focused on chronic HBV(e.g. Severe Hepatitis B infection, Hepatitis C or D infection, liver fibrosis, hepatocellular carcinoma, intrauterine infection, etc.) were excluded after title review. Twelve studies were excluded after abstract review, three of them were not focusing on chronic HBV and eight lacked HC cases and one was a review article. After full text review, six studies were excluded, two of them not focused on chronic HBV and two were lacking HC cases and the other two were previously written by the same authors(Cheong, J.Y. *et al* [@pone.0019606-Cheong2] and Li, H. Q. *et al* [@pone.0019606-Li1]) of the rest studies, we selected the latest ones[@pone.0019606-Cheong1], [@pone.0019606-Li2]. The extraction process was showed in [Fig 1](#pone-0019606-g001){ref-type="fig"}.

![Flow diagram of identifying potential studies in our meta-analysis.](pone.0019606.g001){#pone-0019606-g001}

Finally a total of 12 relevant studies were selected [@pone.0019606-Chen1], [@pone.0019606-Niro1], [@pone.0019606-Hohler1], [@pone.0019606-Cheong1], [@pone.0019606-Ribeiro1], [@pone.0019606-Somi1], [@pone.0019606-Li2], [@pone.0019606-Kim2], [@pone.0019606-Kummee1], [@pone.0019606-Wan1], [@pone.0019606-Xing1], [@pone.0019606-Zhang1] involving 2754 chronic HBV infection cases and 1630 HBV clearance cases. All studies included that the distribution of genotypes in the controls or recovered was consistent with Hardy-Weinberg equilibrium, except for two studies for -857C/T(Chen,D.Q *et al* [@pone.0019606-Chen1])and -308G/A(Xing,P.X. *et al* [@pone.0019606-Xing2]) .The included studies had been conducted on Chinese, Korean, Thai, Italian, Iranian, Brazilian and German participants. A summary of characteristics of these 12 included studies was showed in [Table 1](#pone-0019606-t001){ref-type="table"}.

10.1371/journal.pone.0019606.t001

###### Characteristics of Studies Included in the Meta-analysis.

![](pone.0019606.t001){#pone-0019606-t001-1}

  Studies(Year/Countries)                                            Age (mean±SD)                 Case of CHB(Males/%)         Case of HC(Males/%)     Methods           Studied Polymorphisms                     Findings              
  -------------------------------------------------------- --------------------------------- --------------------------------- ---------------------- ------------ ------------------------------------ --------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hohler, T.[@pone.0019606-Hohler1](1998/ Germany)                        NA                                NA                         71(NA)            32(NA)                    PCR                              −238,−308                                                                   The *TNF-\<alpha\>*−238 GG statistically significant differences between the CHB and recovered individuals
  Kim, Y. J.[@pone.0019606-Kim1](2003/Korea)                Male 49.9±10.4;Female 50.8±10.6   Male 54.7±10.9;Female 53.6±11.0        1109(74.4)        291(65.5)    Single base primer extension assay   −163,−238,−308, −857,−863, 1031                                                        The *TNF-\<alpha\>*-308 AA or GA or -863 C/C were strongly associated with the resolution of HBV infection
  Zhang,P.A [@pone.0019606-Zhang1](2004/China)                         54.7±14.8                         56.4±14.0                   131(67.9)         165(66.1)                 PCR-RFLP                     −238,−308,−857 −863,                                                               The *TNF-\<alpha\>*-308 A allele and -863 A allele may have a favorable effect in the clearance of HBV.
  Li, H. Q.[@pone.0019606-Li1](2006/China)                            33.37±12.67                       34.68±11.34                  433(81.8)         244(55.8)                   PCR                             −238, −857              The frequency of -238GG genotype in self-limited group was significantly higher than chronic HBV group .The frequency of *TNF-\<alpha\>*-857 CC in chronic HB group was significantly higher than self-limited group
  Niro, G. A.[@pone.0019606-Niro1](2005/Italy)                           52±12                           46.3±7.4                    184(81.5)          96(79.2)              DNA sequencing                  −238,−308, −863,−1031                                                           The *TNF-\<alpha\>*-308GG was associated with an unfavorable prognosis in patients with chronic HBV infection.
  Cheong, J. Y.[@pone.0019606-Cheong1](2006/South Korea)              37.74±8.90                        47.96±s8.77                  261(75.1)         204(72.5)    Single base primer extension assay              −238,−308                                                                      The *TNF-\<alpha\>* −308 and −238 were not different between the clearance and the persistence group
  Somi, M. H.[@pone.0019606-Somi1](2006/Iran)                             NA                                NA                        100(NA)            91(NA)                    PCR                                −308                                                                                The *TNF-\<alpha\>*-308 A had no association with development of chronic HBV infection
  Kummee, P.[@pone.0019606-Kummee1](2007/Thailand)                With HCC: 50.8±13.9                    51.0±12.3              With HCC: 100(68.0)    100(48.0)                 PCR-RFLP                        −238,−308, −863                              The *TNF-\<alpha\>*-863 A/A or A/C genotype were associated with increased the *TNF-\<alpha\>* levels in the liver in response to HBV infection and induced hepatocyte damage.
                                                                 Without HCC:57.5±14.2                                          Without HCC:50(60.0)                                                                                      
  Ribeiro, C. S.[@pone.0019606-Ribeiro1](2007/Brazil)                  37±11.65                          39.5±10.2                    30(60.0)          41(48.8)                   PCR                                −308                                                                          The *TNF-\<alpha\>*-308 G/A had no association between chronic patients and self-limited infection
  Xing,P,X[@pone.0019606-Xing1](2007/China)                           39.65±19.3                         38.5±18.2                   111(85.6)         100(66.0)                Gene Chips                          −238,−308                               The *TNF-\<alpha\>*-308 GG and G allele were higher in chronic HBV infection group than control group, but no association between *TNF-\<alpha\>*−238 and HBV infection was found.
  Chen, D. Q.[@pone.0019606-Chen1] (2010/China)                        40.9±10.9                            NA                       252 (60.7)        109 (55.0)                PCR-RFLP                     −238,−308,−857 ,−863                          The *TNF-\<alpha\>*-308 G/G genotype was more frequent in patients than controls, while the frequencies of TNF -308 A/G genotype was higher in controls than in the patient group
  Wan,P.Q[@pone.0019606-Wan1](2010/China)                              54.7±14.8                         56.4±14.0                    74(59.5)          64(62.5)                 PCR-RFLP                          −857, −863                                                                            In Guangxi population, the *TNF-\<alpha\>*-863 AA might go against the clearance of HBV.

Abbreviations: CHB, chronic HBV infection; HC, HBV clearance; HCC, hepatocellular carcinoma; PCR, polymerase chain reaction; PRLP, restriction fragment length polymorphism; NA, Not Applicable.

Meta-analysis {#s3b}
-------------

[Table 2](#pone-0019606-t002){ref-type="table"} lists the results of the meta-analysis and heterogeneity test. Because the study by Kummee *et al* [@pone.0019606-Kummee1] contained a large number of individuals with HCC, subjects with or without HCC were included in our studies.

10.1371/journal.pone.0019606.t002

###### Meta-analysis of effect of TNF-α promoter polymorphisms on the risk of HBV persistence.

![](pone.0019606.t002){#pone-0019606-t002-2}

              Genotype comparisons         NO. of CHB     NO. of HC    OR \[95% CI,\]        Z (*p* value)         Heterogeneity of study design                                                           
  ------- ----------------------------- ---------------- ------------ ---------------- -------------------------- ------------------------------- ------------ ------------------------------------------- -----------
  −1031      T allele *vs.* C allele        Overall          1617           495            0.86\[0.68,1.08\]                1.27(0.21)                0.01                       1(0.90)                       0%
                   TT *vs.* CC              Overall          827            263            0.54\[0.29,1.02\]                1.89(0.06)                0.21                       1(0.65)                       0%
                 TT *vs.* TC +CC            Overall          1222           379            0.82\[0.65,1.05\]                1.55(0.12)                0.06                       1(0.81)                       0%
                 CC *vs.* TC +TT            Overall          1222           379            1.77\[0.94,3.31\]                1.78(0.08)                0.26                       1(0.61)                       0%
  −863       C allele *vs.* A allele        Overall          2450           1387           0.91\[0.78,1.07\]                1.11(0.27)                8.40                       5(0.14)                       40%
                                             Asian           2208           1262           0.91 \[0.77,1.08\]               1.06 (0.29)               8.40                       4(0.08)                       52%
                 ***CC vs. AA***         ***Overall***    ***1312***     ***743***      ***0.64\[0.42,0.97\]***          ***2.09 (0.04)***         ***5.11***                 ***5(0.40)***                 ***2%***
                                          ***Asian***     ***1107***     ***676***      ***0.64\[0.42,0.99\]***          ***2.01 (0.04)***         ***5.10***                 ***4(0.28)***                 ***22%***
                 CC *vs.* CA+AA             Overall          1881           1065           0.95\[0.68,1.33\]                0.29 (0.77)              17.06                      5(0.004)                       71%
                                             Asian           1697           969            0.97\[0.65,1.44\]                0.16(0.87)               17.06                      4(0.002)                       77%
               ***AA vs. CA+CC***        ***Overall***    ***1866***     ***1065***     ***1.60 \[1.06,2.41\]***         ***2.25(0.02)***          ***6.21***                 ***5(0.29)***                 ***19%***
                                          ***Asian***     ***1682***     ***969***      ***1.60\[1.05,2.45\]***          ***2.18(0.03)***          ***6.21***                 ***4(0.18)***                 ***36%***
  −857       C allele *vs.* T allele         Asian           1993           851            1.04\[0.85,1.28\]                0.38(0.70)                5.55                       2(0.06)                       64%
                   CC *vs.* TT               Asian           1215           527            0.90\[0.51,1.59\]                0.35(0.73)                2.20                       2(0.33)                       9%
                 CC *vs.* CT +TT             Asian           1604           689            1.13\[0.69,1.85\]                0.47(0.64)                9.47                      2(0.009)                       79%
                 TT *vs*. CT+CC              Asian           1604           689            1.15\[0.65,2.01\]                0.47(0.64)                2.08                       2(0.35)                       4%
  −308     ***G allele vs. A allele***   ***Overall***    ***2175***     ***1171***     ***1.30\[1.04,1.63\]***          ***2.30(0.02)***          ***7.50***                 ***7(0.38)***                 ***7%***
                                          ***Asian***     ***1832***     ***964***      ***1.41\[1.08,1.83\]***          ***2.56(0.01)***          ***4.89***                 ***4(0.30)***                 ***18%***
                                            European         304            159            1.15\[0.70,1.89\]                0.56(0.57)                0.58                       1(0.45)                       0%
                   GG *vs.* AA              Overall          2012           1178           0.62\[0.23,1.67\]                0.94(0.35)                0.98                       6(0.98)                       0%
                                             Asian           1785           1047           0.67\[0.19,2.33\]                0.64(0.52)                0.44                       3(0.93)                       0%
                                            European         206             97            0.35\[0.04,2.95\]                0.97(0.33)                0.02                       1(0.89)                       0%
               ***GG vs. GA+AA***        ***Overall***    ***1967***     ***1012***     ***1.35\[1.08,1.70\]***          ***2.59(0.01)***          ***9.20***                 ***7(0.24)***                 ***24%***
                                          ***Asian***     ***1682***     ***843***      ***1.47\[1.13,1.91\]***          ***2.85(0.004)***         ***5.58***                 ***4(0.23)***                 ***28%***
                                            European         384            258            1.31\[0.90,1.91\]                1.41(0.16)                0.54                       2(0.76)                       0%
                 AA *vs.* GA +GG            Overall          2271           1373           1.57\[0.59,4.17\]                0.90(0.37)                1.33      6(0.97)[\*](#nt102){ref-type="table-fn"}       0%
                                             Asian           1836           1113           1.65\[0.40,6.77\]                0.69(0.49)                0.24                       2(0.89)                       0%
                                            European         384            258            1.49\[0.47,4.71\]                0.68(0.50)                0.26                       2(0.88)                       0%
  −238       G allele *vs.* A allele        Overall          2715           1588           0.92\[0.72,1.18\]                0.65(0.52)               12.25                       8(0.14)                       35%
                                             Asian           2421           1451           1.01 \[0.77,1.33\]               0.10(0.92)                8.36                       6(0.21)                       28%
                                            European         294            137            0.50 \[0.77,1.33\]               1.87(0.06)                1.22                       1(0.27)                       18%
                   GG *vs.* AA              Overall          2281           1384           0.88\[0.32,2.45\]                0.52(0.70)                0.52      4(0.97) [\*](#nt102){ref-type="table-fn"}      0%
                                             Asian           2065           1265           0.83 \[0.25,2.70\]               0.23(0.75)                0.23                       2(0.89)                       0%
                                            European         216            119            1.07 \[0.14,8.28\]               0.24(0.95)                0.24                       1(0.62)                       0%
                 GG *vs.* GA+AA             Overall          2498           1486           0.90\[0.70,1.16\]                0.42(0.42)               14.68                       8(0.07)                       46%
                                             Asian           2243           1358           1.01\[0.77,1. 32\]               0.07(0.95)                9.52                       6(0.15)                       37%
                                         ***European***   ***255***      ***128***      ***0.45\[0.22,0.93\]***          ***2.15(0.03)***          ***1.77***                 ***1(0.18)***                 ***44%***
                 AA *vs*. GA +GG            Overall          2498           1486           1.08\[0.39,2.98\]                0.14(0.89)                0.66                       4(0.96)                       0%
                                             Asian           2243           1358           1.18\[0.36,3.86\]                0.27(0.79)                0.20                       2(0.90)                       0%
                                            European         255            128            0.81\[0.11,6.16\]                0.20(0.84)                0.34                       1(0.56)                        0

\*-308 A/A and -238 A/A were rare genotypes. Therefore, some studies had to be excluded because they contained no individuals carrying these genotypes. In the study on -308 AA *vs*. GA +GG, the report by Kummee *et al* [@pone.0019606-Kummee1] was excluded; in -238 GG *vs*. AA and -238 AA *vs*. GA +GG, Cheong *et al* [@pone.0019606-Cheong1] and Li *et al* [@pone.0019606-Li1] were excluded.

Abbreviations: CHB, chronic HBV infection; HC, HBV clearance; OR, odds ratio; CI, confidence interval; df, degree of freedom.

For *TNF-\<alpha\>*-1031T/C and, -857C/T, we found no association between the polymorphisms and HBV clearance. For *TNF-\<alpha\>*-863, overall, we found that compared to -863 AA,*TNF-\<alpha\>*-863 CC genotype was associated with chronic HBV clearance (-863 CC *vs.* AA:OR, 0.64; 95% CI, \[0.42, 0.97\]; p = 0.04) ([Fig 2](#pone-0019606-g002){ref-type="fig"}). When we excluded the subjects with HCC, the signification seemed to be weaken(OR, 0.66; 95% CI, \[0.43, 1.00\]; p = 0.05),implying that -863 CC might play a relatively different role in HCC patients. In a subgroup analysis of *TNF-\<alpha\>*-863 CC *vs.* AA by ethnicity, the pooled OR was significant in Asians (OR, 0.64; 95% CI, \[0.11, 0.99\]; p = 0.04). In addition, the result of AA *vs.* CA+CC model showed that -863 AA maybe a risk factor for HBV persistence (overall: OR, 1.60; 95% CI, \[1.06, 2.41\]; p = 0.02;Asian: OR, 1.60; 95% CI, \[1.05, 2.45\]; p = 0.02) which implied the counteractive function between -863 CC and -863 AA in virus clearance. A European subgroup analysis was not conducted because only one study [@pone.0019606-Niro1] was available.

![OR of HBV infection associated with *TNF-\<alpha\>*-863 C/A for the CC genotype compared with the AA genotypes and AA compared to the CA+AA genotype.](pone.0019606.g002){#pone-0019606-g002}

When we performed analysis on *TNF-\<alpha\>*-308 G/A we found two models had statistic significance(G allele *vs.* A allele: OR, 1.30; 95% CI, \[0.104, 1.63\]; p = 0.02 . GG *vs.* GA+AA: OR, 1.35; 95% CI, \[1.08, 1.70\]; p = 0.01) ([Fig. 3](#pone-0019606-g003){ref-type="fig"}) indicating that -308 G might be an unfavorable factor for the elimination of HBV. In subgroup analysis, the result of Asian group was similar (G allele *vs.* A allele:OR, 1.41; 95% CI, \[1.08, 1.83\]; p = 0.01; GG *vs.* GA+AA: OR, 1.47; 95% CI, \[1.13, 1.91\]; p = 0.004) while the European group lacked such an association. We also performed an analysis for East Asian individuals by removing a study conducting on Iraqi(Somi, M. H [@pone.0019606-Somi1]) from Asian group , the result still stable(G allele *vs.* A allele:OR, 1.49; 95% CI, \[1.12, 1.98\]; p = 0.006; GG *vs.* GA+AA: OR, 1.56; 95% CI, \[1.17, 2.08\]; p = 0.002). When we excluded the subjects with HCC, the results remained similar(data not show).

![OR of HBV infection associated with *TNF-\<alpha\>*-308 G/A for the G allele compared with the A allele and the GG genotype compared with the GA+AA genotypes.](pone.0019606.g003){#pone-0019606-g003}

Interestingly, significantly increased risks were observed in the European population (-238 GG *vs.* GA+AA: OR, 0.45; 95% CI, \[0.22, 0.93\]; *p* = 0.03), but not in the Asian population or overall analysis.

Tests of heterogeneity {#s3c}
----------------------

We found heterogeneities in three studies: (-863 CC *vs.* CA+AA, overall: χ^2^ = 17.06, *p* = 00.004, I^2^ = 71%; Asian: χ^2^ = 17.06, *p* = 0.002, I^2^ = 77%; -857 CC *vs.* CT +TT , χ^2^ = 9.47, *p* = 0.009, I^2^ = 79%) ([Table 2](#pone-0019606-t002){ref-type="table"}). A random-effects model was employed in these studies.

Publication bias {#s3d}
----------------

Begg\'s funnel plot and Egger\'s test were performed to access the publication bias of the studies. No evidence of publication bias showed in -308 G allele *vs.* A allele or -308 GG *vs.* AA model (funnel plot data not show, Egger\'s test p = 0.470 and 0.556,respectively). However, funnel plot showed some asymmetry in -863 CC *vs.* AA and -863 AA *vs.* CA+CC models([Fig 4](#pone-0019606-g004){ref-type="fig"}) and Egger\'s proved the existence of publication in these two models(p = 0.041 and 0.038, respectively). We excluded one study from the meta-analysis to see whether the publication bias still presented. The results showed that after the exclusion of study Chen, D. Q. *et al* [@pone.0019606-Chen1], the publication bias was eliminated(funnel plot showed in [Fig 4](#pone-0019606-g004){ref-type="fig"}, Egger\'s test -863 CC *vs.* AA:p = 0.785; -863 AA *vs.* CA+CC:p = 0.541),and the conclusion still stable(-863 CC *vs.* AA: OR, 0.42; 95% CI, \[0.23, 0.77\]; p = 0.005; -863 AA *vs.* CA+CC: OR, 2.44; 95% CI, \[1.34, 4.45\]; p = 0.003).

![Funnel plot analysis to examine publication bias.\
Some asymmetry in -863 CC vs. AA (A) and -863 AA vs. CA+CC (A). After one study removed, the publication bias was eliminated. See -863 CC vs. AA (B) and -863 AA vs. CA+CC (B).](pone.0019606.g004){#pone-0019606-g004}

Discussion {#s4}
==========

The mechanism of effective clearance of HBV from the human body is likely related to both environmental and host genetic factors. Several studies have reported that *TNF-\<alpha\>* plays an important role in HBV clearance. In an *in vitro* study, *TNF-\<alpha\>* was reported to be able to accelerate HBV mRNA destruction, and inhibit the replication of HBV[@pone.0019606-Koziel1]. An *in vivo* study also found that TNF limited chronic infection by destabilizing HBV nucleocapsids and reducing the cccDNA[@pone.0019606-Puro1]. Furthermore, a clinical study showed that elevation of *TNF-\<alpha\>* levels in *IFN-\<alpha\>*treated patients led to HBV elimination[@pone.0019606-Bradham1].

In the current study, we performed a meta-analysis to examine the association between the SNPs in the promoter region of *TNF-\<alpha\>* and the outcome of HBV infection. According to our findings, the presence of G at the position -308 of *TNF-\<alpha\>* promoter gene polymorphisms increased the risk of HBV persistent infection significantly while -308 A may have a positive effect in virus clearance. Similar conclusion was drew by Zheng, M. H. *et al* [@pone.0019606-Zheng1] who also performed a meta-analysis focus on healthy individual(including spontaneously recovered case)and Chronic hepatitis B patient, they found that -308 A allele was a protective factor for CHB infection, especially in Mongoloid populations. Our analysis was restricted in CHB and HC case, thus our case size was smaller, but higher specificity would provide us more reliable evidence to our conclusion. Taken together, -308 A may play a crucial role in anti-virus mechanism in human body; it can not only protect healthy people from HBV infection but also enhance the scavengingof virus while being infected. This virus clearing function of *TNF-\<alpha\>* --308A allele was associated with the enhancement of *TNF-\<alpha\>* transcriptional activation as well as production [@pone.0019606-Wilson1], [@pone.0019606-Abraham1].

Our study showed that -863 CC and -863 AA might be another important factors in HBV clearance. Previous study reported that the -863 C/A performed their protective or deteriorative function for CHB infection through a difference way that -863 A allele can lower *TNF-\<alpha\>* promoter activity and plasma levels by weakening the affinity between specific protein and the segment of *TNF-\<alpha\>* promoter spanning from position −876 to position −845 [@pone.0019606-Skoog1].

Although the association between *TNF-\<alpha\>* and HCC patient has not been clearly understood, our studies gave some indirect evidence on a different response to the *TNF-\<alpha\>* in CHB and HCC individuals, for the discard of HCC cases from the analysis could affect the results, especially in -863 CC *vs.* AA model, thus, caution should be paid in this result and more investigations are demanded to interpret the relationship among *TNF-\<alpha\>* and HCC and CHB.

In addition, we found that genotype GG at position -238 of TNF-α promoter was associated with decreased risk of chronic HBV persistence in European populations which supports the study of Hohler *et al* [@pone.0019606-Hohler1]. However, the results differed from the study of Lu *et al* [@pone.0019606-Lu1]. The current results suggest that ethnicity may have played an important role in HBV infection outcome, leading to results inconsistent with that of others. Further research is needed to demonstrate the underlying cause for this inconsistency.

In our study, other polymorphisms in the *TNF-\<alpha\>* promoter (-1031T/C,-857C/T) did not show any association with HBV outcome, which is different from some previous reports [@pone.0019606-Kim1], [@pone.0019606-Hohler1], [@pone.0019606-Li1]. Possible explanations for this difference are a lack of data, and ethnicity diversity.

Our study provided a more believable result due to a larger size sample, and provides explanations for the inconsistencies observed in previous studies. Meta-analysis is a powerful statistical tool that provides a consensus by combining the data from diverse studies that reveal inconsistent results on the same problem. Some results of our study did not show any statistical significance although we combined relatively large numbers of studies. However, subgroup analysis by ethnicity showed a statistical significant result. Hence, a meaningful outcome can be produce only when it is correctly used. On the other hand, the more studies included, the more accurate the results would be.

In conclusion, this study provides evidence of a positive association between HBV clearance and *TNF-\<alpha\>* promoter -863 CC. Conversely, -308 GG/GG+GA genotypes increased the risk of chronic infection. These genotypes might affect the outcome of HBV infection through regulation of *TNF-\<alpha\>* transcriptional activation and production. Ethnic diversity may complicate the outcome of infection. More studies of individuals of diverse ethnicities will be necessary to determine the effects of *TNF-\<alpha\>* promoter polymorphisms on the outcome of HBV infection.

**Competing Interests:**The authors have declared that no competing interests exist.

**Funding:**The work was supported by the National Basic Research Program (973 Program) (2007CB512905), National Natural Science Fund (30771918), the State S&T Projects (11th Five Year) (2008ZX10002- 007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

[^1]: Conceived and designed the experiments: QX ZC FC. Performed the experiments: QX LFZ DCL. Analyzed the data: QX LFZ FC. Contributed reagents/materials/analysis tools: QX LFZ DCL. Wrote the paper: QX FC.
